Global X Genomics & Biotechnology ETF holds a quantitatively derived Negative Morningstar Medalist Rating. The rating indicates the model sees limited potential for the strategy to outperform peers on a risk-adjusted basis over a full market cycle.
Global X Genomics & Biotechnology ETF GNOM
Morningstar’s Analysis GNOM
Will GNOM outperform in the future?
Get our overall rating based on a fundamental assessment of the pillars below.
People Pillar
Parent Pillar
- Current Portfolio Date
- Equity Holdings —
- Bond Holdings —
- Other Holdings —
- % Assets in Top 10 Holdings 54.9
|
Top 10 Holdings
|
% Portfolio Weight
|
Market Value USD
|
Sector
|
|---|---|---|---|
Moderna Inc | 11.91 | 13M | Healthcare |
Twist Bioscience Corp | 6.26 | 7M | Healthcare |
10x Genomics Inc Ordinary Shares - Class A | 6.03 | 6M | Healthcare |
Illumina Inc | 5.87 | 6M | Healthcare |
Natera Inc | 5.61 | 6M | Healthcare |
Guardant Health Inc | 5.15 | 5M | Healthcare |
Genscript Biotech Corp Class H | 3.67 | 4M | Healthcare |
Bio-Techne Corp | 3.62 | 4M | Healthcare |
Qiagen NV | 3.40 | 4M | Healthcare |
Vertex Pharmaceuticals Inc | 3.35 | 4M | Healthcare |